Hawaii Pacific Neuroscience

1. Novartis Pharmaceuticals Corporation $470,189 10 payments
2. Eisai Inc. $456,458 147 payments
3. SK Life Science, Inc. $155,954 39 payments
4. Ucb SA $150,909 7 payments
5. Biogen, Inc. $114,925 3 payments
6. Sunovion Pharmaceuticals Inc. $67,045 54 payments
7. Jazz Pharmaceuticals Inc. $64,793 27 payments
8. Ipsen Pharma SAS $55,417 124 payments
9. LivaNova USA, Inc. $50,891 20 payments
10. Merz Pharmaceuticals, LLC $41,400 6 payments

1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $408,361 4 payments
2. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $267,768 22 payments
3. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $188,691 125 payments
4. An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures $150,909 7 payments
5. A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures $67,045 54 payments
6. A Phase 2B 12-Week Double-Blind Placebo-Controlled Randomized Parallel Group Multicenter Study of the Safety and Efficacy of Jzp385 in the Treatment of Adults With Moderate to Severe Essential Tremor $64,793 27 payments
7. Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease $53,921 1 payment
8. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy $52,254 1 payment
9. A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity $37,437 115 payments
10. 059566 $36,883 9 payments

1. Other $32,738 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.